The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.
If you hold Elevance Health (ELV) stock, you’ve been rewarded for believing in a well-run, diversified health insurer
The stock sits near its 52-week high after a strong run, and management just raised its earnings guidance for the year. But when expectations are this high, it’s worth asking what could go wrong. For Elevance, the biggest risk isn’t a hypothetical threat from the outside; it’s a large, well-known problem deep inside the business that the market seems to be looking past.
The company’s story is one of two very different businesses right now. While its Commercial and Medicare Advantage segments are performing well, its large Medicaid division is acting as a significant drag on results. The core risk is that this problem proves larger and more stubborn than investors currently appreciate, forcing a re-evaluation of the company’s overall health.